What Is Treatment-Resistant Depression? A Clear Guide

TL;DR:

• Treatment-resistant depression affects nearly 30% of people with major depressive disorder who do not respond after two proper medication trials. Proper diagnosis requires thorough review of past treatments, consideration of underlying health issues, and understanding biological and psychological causes. Established options include medication changes, psychotherapy, ECT, rTMS, and esketamine (Spravato, FDA-approved), with ketamine used off-label and psilocybin still investigational. Advocacy helps people get personalized, comprehensive care.

Treatment-resistant depression is defined as major depressive disorder that fails to improve after at least two adequate antidepressant trials, each at a proper dose and duration. This is not a rare edge case. Nearly 30% of people with major depressive disorder meet the clinical criteria for treatment-resistant depression, also called refractory depression in some clinical settings. If you or someone you love has tried multiple medications without real relief, this guide is written for you. The options now go well beyond standard antidepressants, and understanding what treatment-resistant depression is can be the first step toward finding what helps you.

What is treatment-resistant depression, and how is it diagnosed?

Treatment-resistant depression is defined clinically as a failure to respond satisfactorily after at least two antidepressant monotherapy trials, each conducted at an adequate dose and for an adequate duration, typically six to eight weeks or longer. The word “adequate” carries real weight here. A trial that was cut short, underdosed, or poorly adhered to does not count as a genuine failed attempt.

This is where the concept of pseudoresistance becomes critical. Medication nonadherence rates among people with depression range from 30–60%. That means a significant portion of people labeled as treatment-resistant may actually have been misclassified due to incomplete trials, wrong diagnoses, or untreated medical conditions. Before accepting a TRD label, a thorough review of every prior treatment is necessary.

Clinicians are also beginning to use a broader concept called Difficult-to-Treat Depression, or DTD. DTD reorients care away from simply counting failed medication trials and toward a fuller picture: symptom patterns, functional impairment, psychosocial stressors, and comorbid conditions. The goal shifts from chasing remission at all costs to optimizing stability and quality of life over time.

A comprehensive diagnostic approach matters enormously. Conditions like thyroid disorders, sleep apnea, chronic pain, and PTSD can all mimic or worsen depression. Ruling these out, or treating them alongside depression, changes the clinical picture significantly.

What are the biological and psychological causes of treatment-resistant depression?

Depression that doesn’t respond to treatment is rarely caused by a single factor. The biology is genuinely complex, and understanding the contributing causes helps explain why no single pill works for everyone.

Neuroinflammation is an active area of research in refractory depression. In some people with elevated CRP and other inflammatory markers, the monoamine system that most antidepressants target may not be the main problem, which could help explain why serotonin-based drugs alone sometimes fall short. This research is still developing and is not yet a routine basis for treatment decisions.

Pharmacogenetics adds another layer. Genetic differences in CYP2D6 and CYP2C19 mean that some people metabolize certain antidepressants very quickly, so the drug may not reach effective levels, while others clear them slowly and are more prone to side effects. Pharmacogenomic testing is available and may help guide some prescribing decisions, though its benefit is still debated.

Psychological factors matter just as much. Low cognitive flexibility has been linked to poorer treatment response. People who find it hard to shift thought patterns may stay stuck in depressive cycles even when medication is helping somewhat. This is one reason psychotherapy is an important part of TRD care.

What treatment options exist for people with treatment-resistant depression?

The treatment landscape for refractory depression has expanded considerably in the past decade. The options below range from well-established to investigational, and many people do best with a combination chosen around their history.

Conventional and combination approaches

Optimizing an existing antidepressant, whether by adjusting dose, switching agents, or adding an augmentation medication like lithium or atypical antipsychotics, remains a first step for many patients. Psychotherapy, particularly cognitive behavioral therapy and acceptance-based approaches, can build cognitive flexibility and address psychological contributors that medication alone may not reach. For a broader view of what newer options look like, Mystic’s guide on advanced depression treatments covers the clinical landscape clearly.

Neuromodulation therapies

Electroconvulsive therapy (ECT) is one of the most effective treatments for severe, treatment-resistant depression, with response rates that compare well with medication. Repetitive transcranial magnetic stimulation (rTMS) and theta burst stimulation (TBS) are non-invasive alternatives with good evidence and fewer side effects than ECT. Neuromodulation therapies like ECT and rTMS have established evidence for TRD and are standard options, not only last resorts. Mystic Health does not provide ECT or TMS; specialist centers do.

Ketamine, esketamine, and psychedelic-assisted therapy

Ketamine and esketamine, a form of ketamine marketed as Spravato, act mainly on the glutamate system rather than serotonin. That different mechanism is one reason they can help some people whom standard antidepressants did not. Spravato is a nasal spray FDA-approved for treatment-resistant depression, and for depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behavior. It is given only in certified clinics, with at least two hours of monitoring afterward. Racemic ketamine, such as IV or intramuscular ketamine, is used off-label for depression. Psilocybin-assisted therapy has shown encouraging results in clinical trials, but it is investigational in the US and is not an FDA-approved treatment.

• Spravato (esketamine) is FDA-approved for TRD and administered nasally in a certified clinical setting
• Psilocybin is investigational and not FDA-approved; for depression it is available through clinical trials
• rTMS is often covered by insurance for TRD after failed antidepressant trials
• Pharmacogenomic testing may help guide some medication choices

How can patients and caregivers advocate for better TRD care?

Understanding treatment-resistant depression is one thing. Knowing how to advocate within the healthcare system is another, and it matters just as much.

1. Request a full medication review. Ask your provider to document every prior antidepressant trial, including dose, duration, and whether you actually took it consistently. Careful review of adherence and dosing can reclassify some TRD cases and prevent unnecessary escalation to more intensive treatments.

2. Push for a multidimensional assessment. Depression that doesn’t respond to treatment often has biological, psychological, and social contributors. Ask whether thyroid function, inflammatory markers like CRP, sleep quality, and trauma history have all been evaluated. A mental health treatment plan that addresses all of these factors gives you a better chance of lasting improvement.

3. Ask about pharmacogenomic testing. A cheek swab can show how your body is likely to metabolize some antidepressants. Coverage varies, and the results are one input among many, but they can help inform prescribing.

4. Seek a specialist in TRD. General practitioners and even many psychiatrists may not be current on the full range of options. Academic medical centers, psychiatry practices focused on TRD, and clinics offering neuromodulation or ketamine and esketamine treatment have access to options that many standard outpatient settings do not.

5. Involve caregivers in the conversation. Family members and close caregivers often notice patterns that patients cannot see themselves. Bringing a trusted person to appointments improves the quality of information providers receive. Mystic’s resources on family mental health support offer practical guidance for those in a supporting role.

6. Watch for cascade iatrogenesis. Cycling through multiple ineffective medications without addressing root causes creates its own harm through side effects and lost time. If a treatment is not working after an adequate trial, the answer is not always another medication. Sometimes it is a fundamentally different approach.

Key takeaways

Treatment-resistant depression is a complex condition, not a personal failure, and good care combines accurate diagnosis, assessment of contributing factors, and evidence-based treatments beyond standard antidepressants.

1. 01

   TRD definition

   Failure to respond after two adequate antidepressant trials at proper dose and duration.

2. 02

   Pseudoresistance risk

   30–60% nonadherence rates mean many TRD diagnoses require careful review before escalating care.

3. 03

   Biological drivers

   Neuroinflammation, pharmacogenetic variation, and low cognitive flexibility are among the factors linked to resistance.

4. 04

   Expanded treatment options

   ECT, rTMS, and Spravato have established evidence; ketamine is used off-label; psilocybin remains investigational.

5. 05

   Advocacy matters

   Requesting a full medication review and multidimensional assessment can change the treatment path significantly.

Mystic’s approach to treatment-resistant depression

Treatment-resistant depression is most of what Mystic Health does. We offer Spravato in our certified clinic in Santa Monica, ketamine-assisted psychotherapy (ketamine prescribed off-label, with preparation and integration sessions with a therapist), psychiatry and medication management, and psychotherapy. We do not offer psilocybin, ECT, or TMS.

Every treatment plan at Mystic starts with a medical consultation that looks at what you have already tried, at what dose and for how long, along with your wider health and history. Sometimes the answer is a medication change rather than a new treatment. Spravato is often covered by insurance, and we check your benefits first; ketamine therapy is self-pay, and financing is available. Learn more on our depression page, or book a free discovery call.

FAQ

Recommended

• Advanced Treatments for Depression: What You Need to Know
• Emotional resilience strategies: proven ways to build mental strength
• Your Guide to Spravato Treatment: What to Expect